PRMT6 increases cytoplasmic localization of p21 CDKN1A  in cancer cells through arginine methylation and makes more resistant to cytotoxic agents

Makoto Nakakido; Zhenzhong Deng; Takehiro Suzuki; Naoshi Dohmae; Yusuke Nakamura; Ryuji Hamamoto

doi:10.18632/oncotarget.5143

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

PRMT6 increases cytoplasmic localization of p21^CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents

Makoto Nakakido, Zhenzhong Deng, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura and Ryuji Hamamoto _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:30957-30967. https://doi.org/10.18632/oncotarget.5143

Metrics: PDF 1903 views | HTML 2500 views | ?

Abstract

Makoto Nakakido1,*, Zhenzhong Deng1,*, Takehiro Suzuki2, Naoshi Dohmae2, Yusuke Nakamura1, Ryuji Hamamoto1

1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, MC2115, Chicago, IL 60637, USA

2Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science, Saitama 351–0198, Japan

*These authors have contributed equally to this work

Correspondence to:

Ryuji Hamamoto, e-mail: [email protected]

Keywords: p21^CDKN1A, arginine methylation, PRMT6, subcellular localization, cancer chemoresistance

Received: July 08, 2015 Accepted: August 12, 2015 Published: September 03, 2015

ABSTRACT

p21^CDKN1A is known as a potent inhibitor of cyclin-dependent kinase (CDK), which regulates cell cycle in response to various stimuli, including DNA damage, on the p53-dependent manner. Here we demonstrate that protein arginine methyltransferase 6 (PRMT6) methylates p21 at arginine 156 and promotes phosphorylation of threonine 145 on p21, resulting in the increase of cytoplasmic localization of p21. The cytoplasmic presence of p21 makes cancer cells more resistant to cytotoxic agents. Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5143

Publication Alerts

Research Papers:

PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents

Abstract

PRMT6 increases cytoplasmic localization of p21^CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents